- Company Plans Sale of Commercial Operations -
- Nuvion(R) Pivotal Trial Program Terminated -
- Company Plans Organizational Realignment -
FREMONT, Calif., Aug. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced a significant strategic change to focus the company on the discovery and development of novel antibodies in oncology and select immunological diseases, following a months-long business and portfolio review.
As a result of this new strategic focus, which does not include cardiovascular disease, PDL plans to sell its commercial assets, including its Cardene(R), Retavase(R) and IV Busulfex(R) products, as well as the ularitide development-stage cardiovascular product. Separately, following a recent and routine Data Monitoring Committee (DMC) evaluation of data from the ongoing RESTORE 1 pivotal trial, the company has decided to terminate the Nuvion (visilizumab) phase 3 program in ulcerative colitis due to insufficient efficacy and an inferior safety profile in the visilizumab arm compared to IV steroids alone. In light of these developments, the company will realign its organization this Fall to support its new strategy.
The company will hold a conference call on Tuesday, August 28th at 5:15 pm ET to discuss these decisions and respond to questions. A webcast of the conference call will be available through the PDL website: http://www.pdl.com.
"We believe our planned strategic shift, which leverages our core
technical strengths and expertise in monoclonal antibodies as a
development-stage company, is in the best long-term interests of our
stockholders," said L.
|SOURCE PDL BioPharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved